Part II: Precision Medicine in NSCLC—Implications for Molecular Testing and Treatment

Part II: Precision Medicine in NSCLC—Implications for Molecular Testing and Treatment

Part II: Precision Medicine in NSCLC—Implications for Molecular Testing and Treatment

How can we utilize biomarker testing and the available targeted therapies in our non-small cell lung cancer patients who have genetic alterations?

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The discovery of predictive biomarkers has led to an improvement in overall survival (OS) and progression-free survival (PFS) in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatments. These include sensitizing epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, ROS proto-oncogene 1 (ROS1) gene rearrangements, B-Raf proto-oncogene (BRAF) point mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, and programmed cell death protein ligand 1 (PD-L1) expression. Many targeted therapies are currently and recently approved, with oncologic therapy decisions based on the presence of these mutations and gene rearrangements.

    This activity will review the most recent clinical data and provide expert insights on biomarker testing for genetic alterations in NSCLC, and targeted therapies that are available based on the presence of identified mutations and gene rearrangements.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify appropriate efficacious targeted therapy for the treatment of advanced NSCLC based on molecular and biomarker analysis results
    • Assess biomarkers in metastatic NSCLC to identify novel targeted therapies for these patients
  • Target Audience

    This activity is intended for medical oncologists, thoracic oncologists, pathologists, laboratory professionals, physician assistants, advanced practice oncology nurses, pharmacists, genetic counselors, and other healthcare professionals who treat or manage NSCLC.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires instructors, planners, managers, reviewers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Hossein Borghaei, MS, DO, reported a financial interest/relationship or affiliation in the form of Consultant: Bristol-Myers Squibb Co; AbbVie; Amgen, Inc; AstraZeneca Pharmaceuticals LP; Axiom Biotechnologies, Inc; BioNTech; Boehringer Ingelheim; Cantargia AB; Celgene Corp; Daiichi Sankyo Co, Ltd; EMD Serono, Inc; Genentech, Inc; Genmab; GLG Pharma; HUYA Bioscience; Lilly USA; Merck & Co Inc; Novartis Pharmaceuticals Corp; Pfizer, Inc; Pharma Mar, S.A; Regeneron Pharmaceuticals, Inc; and Takeda Oncology. Data and safety monitoring board: Incyte Corp; Takeda Oncology; University of Pennsylvania; and Daiichi Sankyo Co, Ltd. Received income in any amount from: Pfizer, Inc; Bristol-Myers Squibb/Lilly; and Merck/Celgene. Research grant: Millennium Pharmaceuticals, Inc; and Rgenix. Scientific advisory board with stock options: Sonnet BioTherapeutics, Inc. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

    The planners, managers and reviewers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC;  Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 9/29/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-0000-20-051-H01-P. 

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.5 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.
    Are you requesting ASCP CMLE Credit? If yes, an ASCP CMLE certificate will be emailed to you.

  • Commercial Support

    Supported by educational grants from Bristol-Myers Squibb Company; Genentech; Merck Sharp & Dohme Corp; and Novartis Pharmaceuticals Corp.

  • Terms of Use

    Disclosure of Unlabeled Use    
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit: 
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free